Author, as appears in the article.: Gonzalez-Montes, Y; Osca-Gelis, G; Rodriguez-Romanos, R; Villavicencio, A; González-Bártulos, M; Llopis, F; Clapes, V; Oriol, A; Sureda, A; Escoda, L; Sarrà, J; Garzó, A; Lloveras, N; Gómez, B; Granada, I; Gallardo, D
Department: Medicina i Cirurgia
URV's Author/s: Sarra Escarre, Jose
Keywords: Bone marrow microenvironment Cd200 polymorphisms Disease Expression Genes Glycoprotein Immune checkpoint Immune disfunction Immunity Multiple myeloma Risk Susceptibility Therapeutic target
Abstract: Immune dysfunction in patients with MM affects both the innate and adaptive immune system. Molecules involved in the immune response pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of immune checkpoint molecules in predicting the myeloma control and immunological scape as mechanism of disease progression. We retrospectively analyzed the clinical impact of the CD200 genotype (rs1131199 and rs2272022) in 291 patients with newly diagnosed MM. Patients with a CD200 rs1131199 GG genotype showed a median overall survival (OS) significantly lower than those with CC+CG genotype (67.8 months versus 94.4 months respectively; p: 0.022) maintaining significance in the multivariate analysis. This effect was specially detected in patients not receiving an autologous stem cell transplant (auto-SCT) (p < 0.001). In these patients the rs1131199 GG genotype negatively influenced in the mortality not related with the progression of MM (p: 0.02) mainly due to infections events.
Thematic Areas: Biodiversidade Biotecnología Ciência de alimentos Ciências biológicas i Ciências biológicas ii Ciências biológicas iii Engenharias ii Engenharias iii Farmacia Immunology Immunology and allergy Interdisciplinar Medicina i Medicina ii Medicina iii Medicina veterinaria Nutrição Odontología Química Saúde coletiva Zootecnia / recursos pesqueiros
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: jose.sarra@urv.cat
Record's date: 2024-05-23
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1252445/full
Papper original source: Frontiers In Immunology. 15 1252445-
APA: Gonzalez-Montes, Y; Osca-Gelis, G; Rodriguez-Romanos, R; Villavicencio, A; González-Bártulos, M; Llopis, F; Clapes, V; Oriol, A; Sureda, A; Escoda, L; (2024). CD200 genotype is associated with clinical outcome of patients with multiple myeloma. Frontiers In Immunology, 15(), 1252445-. DOI: 10.3389/fimmu.2024.1252445
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Article's DOI: 10.3389/fimmu.2024.1252445
Entity: Universitat Rovira i Virgili
Journal publication year: 2024
Publication Type: Journal Publications